Climb Bio, Inc. $CLYM Shares Sold by Renaissance Technologies LLC

Renaissance Technologies LLC trimmed its position in shares of Climb Bio, Inc. (NASDAQ:CLYM) by 32.2% during the first quarter, according to its most recent Form 13F filing with the SEC. The firm owned 217,300 shares of the company’s stock after selling 103,300 shares during the period. Renaissance Technologies LLC’s holdings in Climb Bio were worth $1,489,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also modified their holdings of CLYM. Dimensional Fund Advisors LP purchased a new stake in shares of Climb Bio during the 1st quarter worth $715,000. Hsbc Holdings PLC increased its holdings in Climb Bio by 107.2% in the fourth quarter. Hsbc Holdings PLC now owns 24,744 shares of the company’s stock valued at $99,000 after buying an additional 12,800 shares during the last quarter. Seven Fleet Capital Management LP purchased a new position in Climb Bio in the fourth quarter valued at $306,000. Virtu Financial LLC acquired a new stake in Climb Bio in the fourth quarter valued at $43,000. Finally, XTX Topco Ltd raised its stake in Climb Bio by 19.4% in the fourth quarter. XTX Topco Ltd now owns 34,852 shares of the company’s stock valued at $139,000 after buying an additional 5,668 shares in the last quarter. 69.76% of the stock is currently owned by institutional investors and hedge funds.

Climb Bio Stock Up 3.9%

Climb Bio stock opened at $14.39 on Thursday. Climb Bio, Inc. has a 52-week low of $1.54 and a 52-week high of $14.55. The firm has a market capitalization of $826.56 million, a P/E ratio of -17.34 and a beta of 0.08. The firm has a fifty day moving average of $12.53 and a 200-day moving average of $9.53.

Climb Bio (NASDAQ:CLYM) last posted its quarterly earnings data on Thursday, August 6th. The company reported ($0.18) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.21) by $0.03. On average, research analysts expect that Climb Bio, Inc. will post -0.84 EPS for the current fiscal year.

Analyst Ratings Changes

A number of analysts have issued reports on the company. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Climb Bio in a report on Friday, July 17th. Chardan Capital assumed coverage on shares of Climb Bio in a report on Tuesday, May 5th. They set a “buy” rating and a $22.00 price objective on the stock. Oppenheimer lifted their target price on shares of Climb Bio from $10.00 to $18.00 and gave the company an “outperform” rating in a report on Tuesday, April 21st. Mizuho initiated coverage on shares of Climb Bio in a research report on Wednesday, April 15th. They set an “outperform” rating and a $18.00 price objective for the company. Finally, Wedbush raised their price target on Climb Bio from $17.00 to $20.00 and gave the company an “outperform” rating in a report on Monday, July 27th. Two research analysts have rated the stock with a Strong Buy rating, twelve have assigned a Buy rating and one has given a Sell rating to the company. According to MarketBeat, the company has a consensus rating of “Buy” and an average price target of $22.75.

Climb Bio Profile

Climb Bio Therapeutics, Inc is a clinical-stage biotechnology company focused on the discovery and development of engineered protein therapeutics for the treatment of cancer and immune-mediated disorders. The company’s mission centers on designing biologics with enhanced specificity and functional activity to engage key cellular targets and improve patient outcomes in areas of high unmet need.

At the heart of Climb Bio’s approach is its proprietary protein engineering platform, which combines mammalian cell display, directed evolution and computational modeling.